Literature DB >> 18941253

Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody.

Ana María Hernández1, Darién Toledo, Darel Martínez, Tania Griñán, Victor Brito, Amparo Macías, Sailyn Alfonso, Teresa Rondón, Eduardo Suárez, Ana María Vázquez, Rolando Pérez.   

Abstract

1E10 mAb is an anti-Id murine mAb (Ab2 mAb) specific for an Ab1 mAb that reacts with NeuGc-containing gangliosides, sulfatides, and Ags expressed in some human tumors. In preclinical studies, this Ab2 Ab was able to mimic NeuGc-containing gangliosides only in animals lacking expression of these Ags in normal tissues. In this study, we report on the immune responses elicited in 20 non-small cell lung cancer patients treated with 1 mg of aluminum hydroxide-precipitated 1E10 mAb. In the hyperimmune sera from 16 of 20 patients, a strong specific Ab response of both IgM and IgG isotypes against NeuGcGM3 ganglioside was observed. Patient immune sera were able to induce complement-independent cell death of NeuGcGM3-expressing X63 murine myeloma target cells. Significant immunoreactivity to NeuGcGM3 was still detected after the complete abrogation of the reactivity against 1E10 mAb by the adsorption of patient sera with this Ab. We hypothesize that Id(-)Ag(+) Abs could reflect the activation of an autologous idiotypic cascade into the patients. Both Id(+)Ag(+) and Id(-)Ag(+) fractions were separated by affinity chromatography and characterized. Although IgG isotype Abs were found in both fractions, IgM isotype Abs were found only in the Id(-)Ag(+) fraction. Both Id(+)Ag(+) and Id(-)Ag(+) Abs were able to specifically recognize and induce cell death in NeuGcGM3-expressing X63 myeloma target cells. Patients that developed IgG and/or IgM Abs against NeuGcGM3 showed longer median survival times.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941253     DOI: 10.4049/jimmunol.181.9.6625

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

Review 1.  Natural IgM in immune equilibrium and harnessing their therapeutic potential.

Authors:  Srini V Kaveri; Gregg J Silverman; Jagadeesh Bayry
Journal:  J Immunol       Date:  2012-02-01       Impact factor: 5.422

2.  Detection of disease specific sialoglycoconjugate specific antibodies in bronchoalveolar lavage fluid of non-small cell lung cancer patients.

Authors:  Sangeeta Mehta; Rakhee Chhetra; Radhika Srinivasan; Suresh C Sharma; Digambar Behera; Sujata Ghosh
Journal:  Glycoconj J       Date:  2010-05-16       Impact factor: 2.916

3.  Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody.

Authors:  G M Piperno; A López-Requena; A Predonzani; D Dorvignit; M Labrada; L Zentilin; O R Burrone; M Cesco-Gaspere
Journal:  Gene Ther       Date:  2015-07-16       Impact factor: 5.250

Review 4.  Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.

Authors:  Yuniel Fernández-Marrero; Alejandro López-Requena
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 5.  Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.

Authors:  L G Durrant; P Noble; I Spendlove
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

Review 6.  Cancer intelligence acquired (CIA): tumor glycosylation and sialylation codes dismantling antitumor defense.

Authors:  Kayluz Frias Boligan; Circe Mesa; Luis Enrique Fernandez; Stephan von Gunten
Journal:  Cell Mol Life Sci       Date:  2014-12-07       Impact factor: 9.261

Review 7.  Strategies for cancer vaccine development.

Authors:  Matteo Vergati; Chiara Intrivici; Ngar-Yee Huen; Jeffrey Schlom; Kwong Y Tsang
Journal:  J Biomed Biotechnol       Date:  2010-07-11

8.  Cancer targeting vaccines: surrogate measures of activity.

Authors:  John Nemunaitis
Journal:  Hum Vaccin Immunother       Date:  2013-01       Impact factor: 3.452

Review 9.  Cancer stem cells and immunoresistance: clinical implications and solutions.

Authors:  Jordi Codony-Servat; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2015-12

10.  Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective.

Authors:  Roberto E Gómez; Maria L Ardigo
Journal:  Front Oncol       Date:  2012-10-29       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.